Early clinical signals for Placental Mesenchymal Stem Cell Hydrogel in Radiation-induced Skin Injury
ASIDE Oncology · 2025
DOI: 10.71079/aside.onc.122425337 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASIDE Oncology, 2025. Verfasst von Fatma A. Rikabe und 3 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radiation-induced skin injury (RSI) affects 85-90\% of radiotherapy patients, with limited effective treatment options available. A recent Phase II randomized controlled trial investigated the efficacy of placental mesenchymal stem cell (PMSC)-embedded alginate hydrogel for treating moderate-to-severe RSI.
Methods
This commentary analyzes the double-blinded, placebo-controlled trial by Tian et al. (N= 66), which evaluated once-daily PMSC hydrogel application (1× viable PMSCs) for six days in patients with grade II or higher RSI. Primary endpoints included overall recovery rate, wound regression, and dermatitis severity scores.
Results
The PMSC hydrogel group demonstrated statistically significant improvement in healing rates (p ˂ 0.001), with 64% relative risk reduction in wound progression compared to placebo. Radiation-Induced Skin Reaction Assessment Scale scores and pain relief showed significant benefits by Day 6. TGF-β1 biomarker elevation suggested native tissue repair mechanisms. No serious adverse events were reported during the study period. Key constraints include a single-center design, a small sample size, a 15-day follow-up duration, the absence of quality-of-life improvements on the EORTC QLQ-C30, and the lack of reported cancer types or radiation regimen details, limiting generalizability.
Conclusion
The trial presents encouraging preliminary evidence supporting PMSC hydrogel’s potential in accelerating the RSI healing process. However, definitive conclusions regarding practice-change efficacy require confirmation through larger, multicenter Phase III trials with extended follow-up (3-6 months), comprehensive patient-centered outcomes, cost-effectiveness analysis, and through assessment of late effects, including fibrosis.
Zitieren
APA
Rikabe, F. A., Gouda, A., Mohamed, A. H., & Fatima, S. (2025). Early clinical signals for Placental Mesenchymal Stem Cell Hydrogel in Radiation-induced Skin Injury. ASIDE Oncology. https://doi.org/10.71079/aside.onc.122425337
Vancouver
Rikabe FA, Gouda A, Mohamed AH, Fatima S. Early clinical signals for Placental Mesenchymal Stem Cell Hydrogel in Radiation-induced Skin Injury. ASIDE Oncology. 2025. doi:10.71079/aside.onc.122425337
BibTeX
@article{Rikabe2025,
author = {Rikabe, Fatma A. and Gouda, Abdelrhman and Mohamed, Abdelrhman H. and Fatima, Sampana},
title = {Early clinical signals for Placental Mesenchymal Stem Cell Hydrogel in Radiation-induced Skin Injury},
journal = {ASIDE Oncology},
year = {2025},
doi = {10.71079/aside.onc.122425337}
}
EUVIMED